LU92048I2 - Tocilizumab - Google Patents

Tocilizumab

Info

Publication number: LU92048I2
Authority: LU; Luxembourg
Prior art keywords: cell growth; growth inhibitor; synovial cell; antibody; treatment
Prior art date: 1994-10-07

Application number

LU92048C

Other languages

English (en)

Original Assignee

Chugai Pharmaceutical Co Ltd

Kishimoto Tadamitsu

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-07

Filing date

2012-07-20

Publication date

2012-09-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17112746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92048(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-07-20 Application filed by Chugai Pharmaceutical Co Ltd, Kishimoto Tadamitsu filed Critical Chugai Pharmaceutical Co Ltd

2012-09-20 Publication of LU92048I2 publication Critical patent/LU92048I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

LU92048C 1994-10-07 2012-07-20 Tocilizumab LU92048I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP24403594		1994-10-07
PCT/JP1995/001144 WO1996011020A1 (fr)	1994-10-07	1995-06-07	Medicament contre la polyarthrite rhumatoide contenant un antagoniste d'interleukine 6 comme principe actif

Publications (1)

Publication Number	Publication Date
LU92048I2 true LU92048I2 (fr)	2012-09-20

Family

ID=17112746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92048C LU92048I2 (fr)	1994-10-07	2012-07-20	Tocilizumab

Country Status (18)

Country	Link
EP (3)	EP2077120A3 (fr)
JP (1)	JP3067987B2 (fr)
KR (1)	KR100306517B1 (fr)
CN (2)	CN101601861A (fr)
AT (1)	ATE552012T1 (fr)
AU (1)	AU700819B2 (fr)
CA (1)	CA2201781C (fr)
CZ (1)	CZ296919B6 (fr)
DK (1)	DK0783893T3 (fr)
ES (1)	ES2384222T3 (fr)
FI (1)	FI120721B (fr)
HU (1)	HU223602B1 (fr)
LU (1)	LU92048I2 (fr)
NO (4)	NO321089B1 (fr)
PL (1)	PL186506B1 (fr)
PT (1)	PT783893E (fr)
RU (1)	RU2147443C1 (fr)
WO (1)	WO1996011020A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2284271C (fr) *	1997-03-21	2012-05-08	Chugai Seiyaku Kabushiki Kaisha	Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
DK1004315T3 (da) *	1997-08-15	2008-07-21	Chugai Pharmaceutical Co Ltd	Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus
CN101239185A (zh)	1998-03-17	2008-08-13	中外制药株式会社	一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
ES2260905T3 (es)	1998-04-17	2006-11-01	Suntory Limited	Gen que codifica una proteina con actividad de sintesis de aurona.
EP1334731B1 (fr)	2000-10-25	2008-02-27	Chugai Seiyaku Kabushiki Kaisha	Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
JPWO2002066063A1 (ja) *	2001-02-23	2004-06-17	星野　友昭	代謝性骨疾患治療剤
UA80091C2 (en) *	2001-04-02	2007-08-27	Chugai Pharmaceutical Co Ltd	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
RU2299888C2 (ru) *	2001-04-05	2007-05-27	Иммуно-Байолоджикал Лэборэтэриз Ко., Лтд.	Антитело против остеопонтина и его применение
DK1475101T3 (da)	2002-02-14	2011-01-10	Chugai Pharmaceutical Co Ltd	Antistof-holdige farmaceutiske opløsninger
GB2401040A (en)	2003-04-28	2004-11-03	Chugai Pharmaceutical Co Ltd	Method for treating interleukin-6 related diseases
JP2007104901A (ja) *	2004-01-16	2007-04-26	Astellas Pharma Inc	関節リウマチ治療薬のスクリーニング法
US20080145367A1 (en) *	2004-02-11	2008-06-19	Warner-Lambert Compay, Llc	Methods of Treating Osteoarthritis with Il-6 Antagonists
AR048335A1 (es)	2004-03-24	2006-04-19	Chugai Pharmaceutical Co Ltd	Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
RU2293560C2 (ru) *	2005-03-09	2007-02-20	Лидия Николаевна Долгова	Способ лечения хронических гонартритов у больных остеоартрозом
RU2293559C2 (ru) *	2005-03-09	2007-02-20	Лидия Николаевна Долгова	Способ подготовки к любрикантной терапии
WO2006106905A1 (fr)	2005-03-31	2006-10-12	Chugai Seiyaku Kabushiki Kaisha	Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
JO3058B1 (ar) *	2005-04-29	2017-03-15	Applied Molecular Evolution Inc	الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2007039552A1 (fr) *	2005-09-28	2007-04-12	Cytos Biotechnology Ag	Conjugés d’interleukin-1 et leurs utilisations
AU2006300234B2 (en)	2005-10-14	2013-01-10	Chugai Seiyaku Kabushiki Kaisha	Agents for suppressing damage to transplanted islets after islet transplantation
EP1941908B1 (fr)	2005-10-21	2015-08-19	Chugai Seiyaku Kabushiki Kaisha	Agent therapeutique pour maladie de coeur
AR057582A1 (es)	2005-11-15	2007-12-05	Nat Hospital Organization	Agentes para suprimir la induccion de linfocitos t citotoxicos
CN104189907A (zh)	2006-01-27	2014-12-10	学校法人庆应义塾	伴有脉络膜血管生成的疾病的治疗药
DK2006381T3 (en)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
ES2654040T3 (es)	2006-03-31	2018-02-12	Chugai Seiyaku Kabushiki Kaisha	Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
JP5754875B2 (ja)	2006-04-07	2015-07-29	国立大学法人大阪大学	筋再生促進剤
US8080248B2 (en)	2006-06-02	2011-12-20	Regeneron Pharmaceuticals, Inc.	Method of treating rheumatoid arthritis with an IL-6R antibody
AU2007254831B2 (en)	2006-06-02	2012-03-22	Regeneron Pharmaceuticals, Inc.	High affinity antibodies to human IL-6 receptor
US7919095B2 (en)	2006-08-03	2011-04-05	Vaccinex, Inc.	Anti-IL-6 monoclonal antibodies
JP2010095445A (ja) *	2006-12-27	2010-04-30	Tokyo Medical & Dental Univ	Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
TWI438208B (zh)	2007-01-23	2014-05-21	Chugai Pharmaceutical Co Ltd	抑制慢性排斥反應之藥劑
JP5334319B2 (ja)	2007-09-26	2013-11-06	中外製薬株式会社	Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
RU2505603C2 (ru)	2007-09-26	2014-01-27	Чугаи Сейяку Кабусики Кайся	Антитело против рецептора il-6
TWI563002B (en)	2007-09-26	2016-12-21	Chugai Pharmaceutical Co Ltd	Antibody constant region mutant
ES2585480T3 (es)	2007-12-05	2016-10-06	Chugai Seiyaku Kabushiki Kaisha	Anticuerpo anti-NR10 y uso del mismo
TR201808046T4 (tr)	2008-04-11	2018-06-21	Chugai Pharmaceutical Co Ltd	İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
AU2009246430B2 (en)	2008-05-13	2015-07-02	Novimmune S.A.	Anti-IL-6/IL-6R antibodies and methods of use thereof
CN102256623A (zh)	2008-06-05	2011-11-23	独立行政法人国立癌症研究中心	神经浸润抑制剂
US8188235B2 (en)	2008-06-18	2012-05-29	Pfizer Inc.	Antibodies to IL-6 and their uses
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
WO2010107110A1 (fr)	2009-03-19	2010-09-23	中外製薬株式会社	Variant d'une région constante d'anticorps
JP5787446B2 (ja)	2009-03-19	2015-09-30	中外製薬株式会社	抗体定常領域改変体
KR20120024763A (ko)	2009-05-15	2012-03-14	추가이 세이야쿠 가부시키가이샤	항ａｘｌ 항체
EP2432480B1 (fr) *	2009-05-18	2021-05-05	The University of Hong Kong	Compositions et procédés pour traiter une arthrite inflammatoire
WO2011037158A1 (fr)	2009-09-24	2011-03-31	中外製薬株式会社	Régions constantes modifiées d'un anticorps
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es)	2010-01-20	2012-04-11	Chugai Pharmaceutical Co Ltd	Formulaciones liquidas estabilizadas contentivas de anticuerpos
US10435458B2 (en)	2010-03-04	2019-10-08	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variants with reduced Fcgammar binding
JP5904552B2 (ja)	2010-05-28	2016-04-13	国立研究開発法人国立がん研究センター	膵癌治療剤
US9539322B2 (en)	2010-05-28	2017-01-10	National University Corporation Hokkaido University	Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
KR102116202B1 (ko)	2010-11-08	2020-05-28	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
BR112013012213A2 (pt)	2010-11-17	2020-09-01	Chugai Seiyaku Kabushiki Kaisha	moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
AU2011337704B2 (en)	2010-11-30	2017-06-15	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP4987117B2 (ja)	2010-12-27	2012-07-25	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
BR112013021526B1 (pt)	2011-02-25	2021-09-21	Chugai Seiyaku Kabushiki Kaisha	Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
EP2762493B1 (fr)	2011-09-30	2021-06-09	Chugai Seiyaku Kabushiki Kaisha	Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI589299B (zh)	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
US9580501B2 (en)	2011-12-16	2017-02-28	Synthon Biopharmaceuticals B.V.	Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
JP6117915B2 (ja)	2012-05-21	2017-04-19	コリアリサーチインスティテュートオブバイオサイエンスアンドバイオテクノロジーＫｏｒｅａＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅＯｆＢｉｏｓｃｉｅｎｃｅＡｎｄＢｉｏｔｅｃｈｎｏｌｏｇｙ	ミゾコウジュの抽出物またはその分画物を有効成分として含む、ｓｔａｔ３媒介性疾患の予防または治療用医薬組成物
EP3009518B1 (fr)	2013-06-11	2020-08-12	National Center of Neurology and Psychiatry	Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
WO2015046467A1 (fr)	2013-09-27	2015-04-02	中外製薬株式会社	Procédé de production d'un hétéromultimère polypeptidique
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
UA127961C2 (uk)	2014-12-19	2024-02-28	Чугей Сейяку Кабусікі Кайся	Антитіло до латентного міостатину
TW201809008A (zh)	2014-12-19	2018-03-16	日商中外製藥股份有限公司	抗ｃ５抗體及使用方法
TWI844732B (zh)	2015-02-05	2024-06-11	日商中外製藥股份有限公司	包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
RU2730590C2 (ru)	2015-02-27	2020-08-24	Чугаи Сейяку Кабусики Кайся	Композиция для лечения заболеваний, связанных с ил-6
JP7082484B2 (ja)	2015-04-01	2022-06-08	中外製薬株式会社	ポリペプチド異種多量体の製造方法
US10697883B2 (en)	2015-05-19	2020-06-30	National Center Of Neurology And Psychiatry	Method for determining application of therapy to multiple sclerosis (MS) patient
WO2016195088A1 (fr)	2015-06-04	2016-12-08	国立研究開発法人国立精神・神経医療研究センター	Agent thérapeutique contre les maladies mentales ayant un inhibiteur d'il-6 comme principe actif
JP7272794B2 (ja)	2015-11-03	2023-05-12	サノフィ・バイオテクノロジー	ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法
EP3394098A4 (fr)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	Anticorps anti-myostatine et procédés d'utilisation
US11649262B2 (en)	2015-12-28	2023-05-16	Chugai Seiyaku Kabushiki Kaisha	Method for promoting efficiency of purification of Fc region-containing polypeptide
TW202214700A (zh)	2016-03-14	2022-04-16	日商中外製藥股份有限公司	用於癌之治療的細胞傷害誘導治療劑
KR102102734B1 (ko)	2016-08-05	2020-04-22	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
CN108339118A (zh) *	2017-01-23	2018-07-31	瑞阳(苏州)生物科技有限公司	治疗或预防阻塞性睡眠呼吸暂停的药物组合物
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US20200369774A1 (en)	2017-09-13	2020-11-26	Jiangsu Hengrui Medicine Co., Ltd.	Il-6r antibody and antigen binding fragment thereof and medical use
US11692037B2 (en)	2017-10-20	2023-07-04	Hyogo College Of Medicine	Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CA3079053A1 (fr)	2017-11-01	2019-05-09	Chugai Seiyaku Kabushiki Kaisha	Variant d'anticorps et isoforme a activite biologique reduite
US11319375B2 (en)	2018-08-29	2022-05-03	Regeneron Pharmaceuticals, Inc.	Methods and compositions for treating subjects having rheumatoid arthritis
CN109517064B (zh) *	2018-10-10	2020-05-08	北京汇智和源生物技术有限公司	白介素-6的人源化单克隆抗体、其编码基因及应用
CA3128212A1 (fr)	2019-01-31	2020-08-06	Sanofi Biotechnology	Anticorps anti-recepteur de l'il6 pour traiter l'arthrite idiopathique juvenile
WO2020178193A1 (fr)	2019-03-01	2020-09-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthode de traitement de la sarcoïdose
US12297279B2 (en)	2019-06-04	2025-05-13	Sanofi Biotechnology	Compositions and methods for treating pain in subjects with rheumatoid arthritis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5171840A (en)	1988-01-22	1992-12-15	Tadamitsu Kishimoto	Receptor protein for human B cell stimulatory factor-2
EP0399429A1 (fr) *	1989-05-22	1990-11-28	Toray Industries, Inc.	Anticorps monoclonal contre l'interleukine-6 humaine
DE69029015T2 (de) *	1989-07-20	1998-01-22	Tadamitsu Kishimoto	Antikörper gegen menschlichen Interleukin-6-Rezeptor
JP2898064B2 (ja)	1989-08-03	1999-05-31	忠三岸本	ヒトｇｐ１３０蛋白質
DE3939706C1 (fr) *	1989-12-01	1991-03-21	Centre Regional De Transfusion Sanguine, Besancon, Fr
AU648777B2 (en) *	1989-12-04	1994-05-05	Schering Corporation	Method of treating septic shock
JP2898040B2 (ja)	1990-01-26	1999-05-31	忠三岸本	ｇｐ１３０蛋白質に対する抗体
US5210075A (en)	1990-02-16	1993-05-11	Tanabe Seiyaku Co., Ltd.	Interleukin 6 antagonist peptides
JPH0489433A (ja)	1990-07-27	1992-03-23	Hitachi Chem Co Ltd	免疫調節剤
JP2947924B2 (ja) *	1990-11-21	1999-09-13	信和化工株式会社	光学異性体用分離剤
JPH04187645A (ja) *	1990-11-22	1992-07-06	Chuzo Kishimoto	インターロイキン―６作用抑制剤
WO1992019759A1 (fr)	1991-04-25	1992-11-12	Chugai Seiyaku Kabushiki Kaisha	Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
JPH05300338A (ja)	1992-04-17	1993-11-12	Ricoh Co Ltd	複合機
JPH05304986A (ja) *	1992-04-28	1993-11-19	Tosoh Corp	ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
FR2694767B1 (fr)	1992-08-13	1994-10-21	Innotherapie Lab Sa	Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH06134617A (ja)	1992-10-23	1994-05-17	Amada Co Ltd	鋸盤の鋸刃テンション自動調整装置
JP3525221B2 (ja) *	1993-02-17	2004-05-10	味の素株式会社	免疫抑制剤

1995
- 1995-06-07 CN CNA2009101322726A patent/CN101601861A/zh active Pending
- 1995-06-07 EP EP09000787A patent/EP2077120A3/fr not_active Withdrawn
- 1995-06-07 RU RU97108276A patent/RU2147443C1/ru active Protection Beyond IP Right Term
- 1995-06-07 ES ES95921130T patent/ES2384222T3/es not_active Expired - Lifetime
- 1995-06-07 CZ CZ0103497A patent/CZ296919B6/cs not_active IP Right Cessation
- 1995-06-07 CA CA002201781A patent/CA2201781C/fr not_active Expired - Lifetime
- 1995-06-07 EP EP95921130A patent/EP0783893B1/fr not_active Expired - Lifetime
- 1995-06-07 KR KR1019970702209A patent/KR100306517B1/ko not_active Expired - Lifetime
- 1995-06-07 HU HU9701906A patent/HU223602B1/hu active Protection Beyond IP Right Term
- 1995-06-07 AT AT95921130T patent/ATE552012T1/de active
- 1995-06-07 DK DK95921130.1T patent/DK0783893T3/da active
- 1995-06-07 AU AU26303/95A patent/AU700819B2/en not_active Expired
- 1995-06-07 PT PT95921130T patent/PT783893E/pt unknown
- 1995-06-07 EP EP09009350A patent/EP2107070A1/fr not_active Withdrawn
- 1995-06-07 WO PCT/JP1995/001144 patent/WO1996011020A1/fr active IP Right Grant
- 1995-06-07 PL PL95319574A patent/PL186506B1/pl unknown
- 1995-06-07 CN CN2008102100070A patent/CN101361972B/zh not_active Expired - Lifetime
- 1995-10-06 JP JP7284364A patent/JP3067987B2/ja not_active Expired - Lifetime
1997
- 1997-04-04 FI FI971404A patent/FI120721B/fi not_active IP Right Cessation
- 1997-04-04 NO NO19971546A patent/NO321089B1/no not_active IP Right Cessation
2005
- 2005-11-17 NO NO20055446A patent/NO20055446L/no not_active Application Discontinuation
2009
- 2009-05-04 NO NO2009009C patent/NO2009009I2/no unknown
2012
- 2012-07-20 LU LU92048C patent/LU92048I2/fr unknown
2018
- 2018-05-23 NO NO2018017C patent/NO2018017I1/no unknown

Also Published As

Publication number	Publication date
CA2201781A1 (fr)	1996-04-18
HUT77036A (hu)	1998-03-02
FI971404A0 (fi)	1997-04-04
PL319574A1 (en)	1997-08-18
HK1127497A1 (en)	2009-09-25
NO971546D0 (no)	1997-04-04
EP0783893A1 (fr)	1997-07-16
FI971404L (fi)	1997-06-03
WO1996011020A1 (fr)	1996-04-18
NO2009009I1 (no)	2009-05-11
FI120721B (fi)	2010-02-15
NO321089B1 (no)	2006-03-13
CZ103497A3 (en)	1997-08-13
ATE552012T1 (de)	2012-04-15
NO971546L (no)	1997-06-04
CZ296919B6 (cs)	2006-07-12
DK0783893T3 (da)	2012-05-29
AU700819B2 (en)	1999-01-14
EP0783893A4 (fr)	1998-04-22
EP2107070A1 (fr)	2009-10-07
EP2077120A2 (fr)	2009-07-08
CN101361972A (zh)	2009-02-11
AU2630395A (en)	1996-05-02
RU2147443C1 (ru)	2000-04-20
CN101361972B (zh)	2011-05-25
CA2201781C (fr)	2010-01-12
NO2009009I2 (no)	2013-03-18
NO20055446L (no)	1997-06-04
KR100306517B1 (ko)	2001-11-30
CN101601861A (zh)	2009-12-16
NO2018017I1 (no)	2018-05-23
JP3067987B2 (ja)	2000-07-24
PT783893E (pt)	2012-05-24
HU223602B1 (hu)	2004-10-28
EP0783893B1 (fr)	2012-04-04
JPH08208514A (ja)	1996-08-13
PL186506B1 (pl)	2004-01-30
EP2077120A3 (fr)	2009-07-15
ES2384222T3 (es)	2012-07-02

Publication	Publication Date	Title
LU92048I2 (fr)	2012-09-20	Tocilizumab
RU97108276A (ru)	1999-05-20	Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
DK0601386T3 (da)	2003-05-26	Sulfonamider
EA200200688A1 (ru)	2003-02-27	Антагонисты фактора, высвобождающего кортикотропин
NL1002835A1 (nl)	1996-10-14	Synergistisch stabilisatormengsel.
ES2172657T3 (es)	2002-10-01	Inhibidores de trombina.
DE69528528D1 (de)	2002-11-14	Thrombin-inhibitoren
IT1213574B (it)	1989-12-20	Inibitori ureidici di renina utili quali agenti ipertensivi.
GR1000130B (el)	1991-07-31	Διαταξη για την επεξεργασια σπορων.
TR199801255T2 (xx)	1998-10-21	Vitronektin resept�r antagonistleri.
DK0839126T3 (da)	2001-08-06	Fremgangsmåde til fremstilling af organiske nitrogenforbindelser, specielle organiske nitrogenforbindelser og blandinger af sådanne forbindelser samt deres anvendelse som brændstof- og smøremiddeladditiver
EA200100688A1 (ru)	2001-12-24	АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
NO960684L (no)	1996-02-21	Monoklonalt antistoff som induserer apoptose
DK0705100T3 (da)	2003-11-17	Terapeutiske substituerede guanidiner
EA200000728A1 (ru)	2001-02-26	Замещенные 2-бензиламино-2-фенилацетамидные соединения
YU48915B (sh)	2002-11-15	Sulfonilkarbamid i postupak za njegovo dobijanje
FI915126L (fi)	1992-05-15	Mineraloljemellandestillat med foerbaettrade flytegenskaper i koeld.
DK0504307T3 (da)	1994-03-21	Fremgangsmåde til behandling af septisk shock
KR950700305A (ko)	1995-01-16	칼슘 통로 길항제로서 아자바이사이클로 화합물(Azabicyclo compounds as calcium channel antagonists)
PH20015A (en)	1986-08-28	N-(1-(4-amino-6,7-dialkoxy-2-quinazolinyl)-4-piperidyl)-oxazolidine-2,4-diones
ATE53492T1 (de)	1990-06-15	Formulierung von entzuendungshemmenden arzneimitteln.
NO873027D0 (no)	1987-07-20	Korrosjonsinhibitor for drivstoffer.
IT1229153B (it)	1991-07-22	Procedimento per la modificazione di emulsioni di bitume mediante elastomeri.
FR2663945B1 (fr)	1994-09-09	Liquide inhibiteur de combustion auto extinguible.
ES1024466Y (es)	1994-05-01	Bandeja para la formacion de prefabricados de hormigon.